Sign in Sign up for free

Last updated: 27 February 2024 at 5:50pm EST

Georges Gemayel Net Worth




The estimated Net Worth of Georges Gemayel is at least $1.09 Million dollars as of 5 August 2020. Georges Gemayel owns over 10,000 units of Supernus Pharmaceuticals Inc stock worth over $748,717 and over the last 10 years he sold SUPN stock worth over $0. In addition, he makes $342,453 as Independent Director at Supernus Pharmaceuticals Inc.

Georges Gemayel SUPN stock SEC Form 4 insiders trading

Georges has made over 4 trades of the Supernus Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of SUPN stock worth $148,400 on 5 August 2020.

The largest trade he's ever made was exercising 10,000 units of Supernus Pharmaceuticals Inc stock on 5 August 2020 worth over $148,400. On average, Georges trades about 1,075 units every 28 days since 2015. As of 5 August 2020 he still owns at least 24,090 units of Supernus Pharmaceuticals Inc stock.

You can see the complete history of Georges Gemayel stock trades at the bottom of the page.





Georges Gemayel biography

Dr. Georges Gemayel Ph.D. serves as Independent Director of the Company. Since 2010, he has served as a consultant for several biotechnology companies and venture capital funds. From February 2011 to December 2012, Dr. Gemayel served as Executive Chairman of Syndexa Pharmaceuticals Corp., a privately held drug development company. Prior to that, in 2010, Dr. Gemayel served as Executive Chairman of FoldRx until its acquisition by Pfizer. From June 2008 until November 2009, Dr. Gemayel served as President and Chief Executive Officer of Altus Pharmaceuticals, a publicly traded pharmaceutical company. In November 2009, while Dr. Gemayel was President, Chief Executive Officer and a director, Altus Pharmaceuticals filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code and ceased operations at such time. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for Genzyme's global therapeutics, transplant, renal and biosurgery businesses. From 2000 to 2003, Dr. Gemayel was employed as Vice President National Specialty Care for Hoffmann La-Roche, responsible for its U.S. business for dermatology, oncology, transplantation, hepatitis and HIV. Dr. Gemayel joined Hoffmann-La Roche in 1988 and served in various positions of increasing responsibility over his tenure there. Dr. Gemayel received his doctorate in pharmacy from St. Joseph University in Beirut, Lebanon and his Ph.D. in Pharmacology from Paris-Sud University in Paris. France. Dr. Gemayel currently serves as chairman of the board of directors of Oxthera AB, Enterome Bioscience SA and Dynacure, all privately held companies, as well as the chairman of the board of directors of Orphazyme and a director and a member of the audit and governance committees of Momenta Pharmaceuticals (each publicly traded companies).

What is the salary of Georges Gemayel?

As the Independent Director of Supernus Pharmaceuticals Inc, the total compensation of Georges Gemayel at Supernus Pharmaceuticals Inc is $342,453. There are 10 executives at Supernus Pharmaceuticals Inc getting paid more, with Jack Khattar having the highest compensation of $8,123,130.



What's Georges Gemayel's mailing address?

Georges's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.

Insiders trading at Supernus Pharmaceuticals Inc

Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.



What does Supernus Pharmaceuticals Inc do?

pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.



What does Supernus Pharmaceuticals Inc's logo look like?

Supernus Pharmaceuticals Inc logo

Complete history of Georges Gemayel stock trades at Momenta Pharmaceuticals and Supernus Pharmaceuticals Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
5 Aug 2020 MNTA Momenta Pharmaceuticals, Inc. Georges Gemayel
Director
 Option 10,000 $14.84 $148,400
5 Aug 2020
24,090 ↗
29 Jul 2020 MNTA Momenta Pharmaceuticals, Inc. Georges Gemayel
Director
 Option 10,000 $14.84 $148,400
29 Jul 2020
24,090 ↗
19 Jun 2019 MNTA Momenta Pharmaceuticals, Inc. Georges Gemayel
Director
 Option 4,356 $12.64 $55,060
19 Jun 2019
14,090 ↗
20 Jun 2018 MNTA Momenta Pharmaceuticals, Inc. Georges Gemayel
Director
 Option 5,734 $22.30 $127,868
20 Jun 2018
9,734 ↗


Supernus Pharmaceuticals Inc executives and stock owners

Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: